Merck Animal Health has announced a major $895 million investment to expand its manufacturing and research and development facilities in De Soto, Kansas. This marks the company’s largest economic development project to date and one of the most significant private investments in Kansas history.
The expansion includes an $860 million upgrade to Merck Animal Health’s existing biologics manufacturing site and a $35 million investment in new research and development laboratories. The 200,000-square-foot facility will increase filling and freeze-drying capacity for large molecule vaccines and biologics, positioning De Soto as a global Center of Excellence within Merck’s manufacturing network.
Construction is set to begin immediately, generating approximately 2,500 construction jobs. Commercial manufacturing operations are expected to begin by 2030, bringing more than 200 full-time roles to the area.
The research and development component of the project will enhance Merck Animal Health’s global efforts in discovering and developing novel parasiticides and therapeutics, further supporting innovation in animal health.
Strategically located in the Animal Health Corridor, the De Soto facility benefits from close proximity to other leading animal health organizations. This investment strengthens Merck Animal Health’s ability to meet growing demand and reaffirms its commitment to U.S. production, animal health advancements, and community development.
Since 2017, Merck has invested over $12 billion in domestic manufacturing and research, with plans for an additional $9 billion in U.S.-based investments by the end of 2028.
